425: Waters CEO Details Strategic Benefits of BD SpinCo Merger

Waters Corporation's CEO, Udit Batra, outlined the strategic advantages of combining with BD's SpinCo, emphasizing enhanced clinical mass spectrometry and expanded specialty diagnostics.

Summary

• Waters Corporation (Waters) is pursuing a proposed business combination with Augusta SpinCo Corporation (SpinCo), a wholly owned subsidiary of Becton, Dickinson and Company (BD).
• Udit Batra, CEO and President of Waters, highlighted that BD's capabilities in diagnostic laboratory workflows and highly regulated environments will bolster Waters' clinical mass spectrometry efforts.
• The combination is expected to enhance Waters' competitive advantage in specialty labs and esoteric laboratory-developed tests.
• BD's acquisition is anticipated to bring additional automation expertise and greater regulatory resources, accelerating the development of In Vitro Diagnostic (IVD) solutions, including platforms and assays.
• Waters aims to significantly expand its specialty diagnostics footprint, particularly in hospital lab settings, by integrating with BD's Biosciences & Diagnostic Solutions business.
• Long-term goals include delivering high-throughput, automated mass spectrometry diagnostics for multiplex workflows in areas like endocrinology and oncology.
• The merger is expected to leverage Waters' mass spectrometry strength with BD's installed base and sales channel across over 10,000 clinical labs, enabling the attachment of Waters' mass specs to BD systems.
• Waters is in the early stages of integration planning and is assessing all incoming capabilities and opportunities, including the future of selling the Bruker MALDI Biotyper.

Sentiment

Score: 7

Explanation: The filing conveys a generally positive outlook from Waters' management regarding the strategic benefits of the proposed merger, emphasizing growth opportunities and enhanced capabilities. However, this is tempered by extensive cautionary statements regarding numerous risks associated with the transaction's completion and integration.

Positives

• Expected enhancement of Waters' clinical mass spectrometry efforts through BD's diagnostic laboratory workflow and regulatory expertise.
• Anticipated competitive advantage in specialty labs and esoteric laboratory-developed tests.
• Access to BD's automation expertise and regulatory resources to accelerate IVD solution development.
• Significant opportunity to expand Waters' specialty diagnostics footprint, including presence in hospital lab settings.
• Potential to deliver high-throughput, automated mass spectrometry diagnostics for multiplex workflows in endocrinology and oncology.
• Leveraging BD's extensive installed base and sales channel (over 10,000 clinical labs) to integrate Waters' mass spectrometry systems.

Risks

• One or more closing conditions, including regulatory approvals, may not be satisfied or waived on a timely basis or at all.
• A governmental entity may prohibit, delay, or refuse to grant approval, or impose conditions, limitations, or restrictions.
• Required approval by Waters' stockholders may not be obtained.
• The proposed transaction may not be completed on the expected terms, timeframe, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty regarding the expected financial performance of the combined company post-completion.
• Failure to realize the anticipated benefits of the proposed transaction, including synergies, due to delays in completion or integration.
• Difficulties and delays in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• Occurrence of any event that could lead to the termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations may affect the timing or occurrence of the transaction or result in significant costs.
• Evolving legal, regulatory, and tax regimes could impact the transaction.
• Changes in general economic and/or industry-specific conditions or volatility from tariffs.
• Actions by third parties, including government agencies, could affect the transaction.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• Greater than expected difficulty in separating SpinCo's business from other BD businesses.
• Disruption of management time from ongoing business operations due to the pendency of the transaction.
• Other effects of the transaction's pendency on relationships with employees, customers, suppliers, or other counterparties.

Future Outlook

Waters anticipates expanding its specialty diagnostics footprint, particularly in hospital lab settings, and positioning itself to deliver high-throughput, automated mass spectrometry diagnostics for multiplex workflows in endocrinology and oncology. The company expects to accelerate the development of IVD solutions by leveraging BD's automation expertise and regulatory resources.

Management Comments

• "BD's capabilities in diagnostic laboratory workflows and highly regulated environments could play in Waters clinical mass spec efforts."
• "Specialty labs and esoteric laboratory-developed tests as areas where it believes it has a competitive advantage."
• "A modular solution helps labs scale at their own pace and in their own space, which is typically more constrained than in a large core lab."
• "The BD acquisition will bring additional automation expertise as well as greater regulatory resources that the company expects will help it accelerate development of more IVD solutions – from platforms to assays."
• "Waters also sees significant opportunities to expand our specialty diagnostics footprint by combining with BDs Biosciences & Diagnostic Solutions business."
• "This includes expanding our presence in hospital lab settings and positioning ourselves over the longer term to deliver high-throughput, automated mass spec diagnostics that enable multiplex workflows in areas such as endocrinology and oncology."
• "By combining Waters strength in mass spec with BDs significant installed base and sales channel across over 10,000 clinical labs, we see opportunity to offer those customers the ability to attach our mass specs to BD systems."
• Declined to comment on the Bruker MALDI Biotyper, noting the company is in "very early stages of integration planning and will be assessing all incoming capabilities and opportunities."

Industry Context

This proposed business combination reflects a trend towards consolidation and integration in the diagnostics and life sciences tools sectors. By combining Waters' advanced mass spectrometry technology with BD's established presence in clinical labs and diagnostic workflows, the merged entity aims to offer more comprehensive and automated solutions, particularly in the growing IVD and specialty diagnostics markets. This move positions Waters to compete more effectively in areas requiring high-throughput and regulated diagnostic capabilities, leveraging BD's market access and regulatory experience.

Corporate Governance

Stakeholder Impact

• **Shareholders (Waters & BD):** Will be required to vote on the transaction (Waters shareholders) and are subject to the risks and potential benefits of the combined entity's future performance. Information on director/executive officer holdings will be disclosed.
• **Employees (Waters & BD/SpinCo):** Integration planning is underway, which may lead to changes in roles, responsibilities, or retention challenges.
• **Customers (Waters & BD):** Expected to benefit from expanded offerings, integrated systems, and high-throughput diagnostic solutions, particularly in clinical labs and hospital settings.
• **Suppliers:** Relationships may be affected by integration planning and potential changes in procurement strategies for the combined entity.
• **Regulatory Authorities:** The transaction is subject to various regulatory approvals, which could impact its timing and conditions.

Next Steps

• Waters intends to file a registration statement on Form S-4, including a preliminary and definitive proxy statement/prospectus.
• SpinCo intends to file a registration statement on Form 10, serving as an information statement/prospectus.
• Stockholders of Waters will be urged to read the proxy statement/prospectus and other SEC filings carefully.
• Integration planning between Waters and SpinCo is in its very early stages.

Key Dates

Keywords

Waters Corporation, Becton Dickinson, SpinCo, Merger, Acquisition, Mass Spectrometry, Clinical Diagnostics, IVD, Laboratory Automation, Healthcare, Biotechnology, SEC Filing